about
Synthesis of tricyclic 4-chloro-pyrimido[4,5-b][1,4]benzodiazepines.Parallel solution-phase synthesis of a 2,6,8,9-tetrasubstituted purine library via a sulfur intermediate.Synthesis of novel tricyclic pyrimido[4,5-b][1,4]benzothiazepines via Bischler-Napieralski-type reactions.Design and synthesis of a tetracyclic pyrimidine-fused benzodiazepine library.An efficient and regiospecific strategy to N7-substituted purines and its application to a library of trisubstituted purines.A new strategy toward fused-pyridine heterocyclic scaffolds: Bischler-Napieralski-type cyclization, followed by sulfoxide extrusion reaction.Method development for a pyridobenzodiazepine library with multiple diversification points.A cascade reaction with iminium ion isomerization as the key step leading to tetrahydropyrimido[4,5-d]pyrimidines.Synthesis of pyrido[2,3-e]pyrrolo[1,2-a]pyrazine derivatives via tandem iminium cyclization and smiles rearrangement.Synthesis of novel 8,9-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-7(6H)-ones.Synthesis of hexahydrobenzo[b]pyrimido[4,5-h][1,6]naphthyridines via an intramolecular hetero-Diels-Alder reaction.MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.Synthesis of highly substituted 2,3-dihydropyrimido[4,5-d]pyrimidin-4(1H)-ones from 4,6-dichloro-5-formylpyrimidine, amines and aldehydes.Synthesis of novel 4H-pyrimido[1,6-a]pyrimidines via a one-pot three-component condensation.Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes.Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.Design of prodrugs to enhance colonic absorption by increasing lipophilicity and blocking ionization.Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.Aromatic dienophiles. 1. A theoretical study of an inverse-electron demand Diels-Alder reaction between 2-aminopyrrole and 1,3,5-triazine.An efficient synthesis of pyrrolo[2,3-d]pyrimidines via inverse electron demand diels-alder reactions of 2-amino-4-cyanopyrroles with 1,3,5-triazines.Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.Synthesis of novel pyrimidine fused 8-membered heterocycles via iminium ion cyclization reactions.Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.Synthesis of phosphonate 3-phthalidyl esters as prodrugs for potential intracellular delivery of phosphonatesA cascade reaction consisting of Pictet-Spengler-type cyclization and Smiles rearrangement: application to the synthesis of novel pyrrole-fused dihydropteridinesRapid access to pyrimido[5,4-c]isoquinolines via a sulfur monoxide extrusion reactionBis[(para-methoxy)benzyl] phosphonate prodrugs with improved stability and enhanced cell penetrationClarification of the mechanism of the cascade reactions between amino-substituted heterocycles and 1,3,5-triazinesNovel heterocyclic scaffold consisting of indole-fused pteridinesSynthesis of highly substituted 4H-pyrido[1,2-a]pyrimidines via a one-pot three-component condensation reaction
P50
Q31158309-BDE1825F-425C-48FA-A868-8DB0BE463A3AQ33218517-FA7B3551-3043-444D-A778-3840576E0D3CQ33229524-7A914C27-8B24-46D5-93C7-0BF970B2DACBQ33242433-DA8FB65C-7E51-4F84-A1F7-3EF5E1BC3551Q33242438-C33C7F8C-5B37-4B29-AA30-AD61339CA7CFQ33292012-1948DD85-14EB-4DE7-B62B-2E7D2A5A4114Q33318944-98E5462D-9623-4486-809B-7DE1C319AB57Q33318947-7BA05532-E838-4B94-A7E6-74EFD959B67FQ33324718-174BA16E-E789-48E7-ADC9-7FADDCA76E7DQ33589129-B05E46D7-D078-4801-B7FA-07F6576074CFQ33605168-B7C4BFF3-C14B-4982-B7A6-B7A77E9FD212Q33833542-D2CFB8D5-9117-4BF0-8D4C-B2A17370F488Q33878558-5094CA03-3B57-4E9A-AF7A-A8282A9EAF61Q34090423-DBE1E8B2-9391-436D-B9CE-FA7EBACD2D29Q34974372-E06FF743-5679-4A62-9D6B-314692C2F985Q36894669-FB47BE2E-1246-498E-ACC3-7E9378B6E2E1Q40321404-483C237E-DA8E-4FAE-B860-F1C5DC33C6EEQ41848731-8DE1C23F-02C2-42A7-85C9-924A0754FCA4Q42787469-BC2C4B02-DF3E-44C0-BE06-A2DBCE1CC429Q43200571-1D43C98A-216B-4EC5-8640-168EA69F8180Q43724195-7C6A8DBA-BD82-4B3F-89B6-90C5450B3155Q44224395-8FB7B82D-A6C9-4DC7-80EF-C00238B9E41DQ46526609-F2280069-4C45-49FF-80E2-E6B19630F3B2Q46682458-213CC075-D6A0-4666-B496-A1207A81AA57Q46819931-C556936E-6D8B-47D3-8097-091036EE45B9Q46880000-96DBC6F5-AFE9-457F-98BF-737387AB778EQ77937254-D34C145C-1ACC-44C6-A1A2-73D8D1241F75Q79722794-465EB4D7-C945-4939-8255-56A0F7C77477Q79739829-B3CE6432-1EE4-491C-90A7-D7BB4D489828Q80217999-97756B3F-A137-4BD6-8520-7E9E43D52D1FQ81329605-84461F60-C2BA-4BD3-A13D-E70C0C259F0BQ81471652-1B22593B-5B18-489F-BFB7-84A16CF66F5DQ87198084-EEE3090B-6065-4B74-9157-FEBD0176B7A5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Qun Dang
@ast
Qun Dang
@en
Qun Dang
@es
Qun Dang
@nl
Qun Dang
@sl
type
label
Qun Dang
@ast
Qun Dang
@en
Qun Dang
@es
Qun Dang
@nl
Qun Dang
@sl
prefLabel
Qun Dang
@ast
Qun Dang
@en
Qun Dang
@es
Qun Dang
@nl
Qun Dang
@sl
P106
P31
P496
0000-0001-5338-7761